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Abstract
Background: The intracellular second messenger cGMP protects the heart under pathological conditions. We examined
expression of phosphodiesterase 5 (PDE5), an enzyme that hydrolyzes cGMP, in human and mouse hearts subjected to
sustained left ventricular (LV) pressure overload. We also determined the role of cardiac myocyte-specific PDE5 expression in
adverse LV remodeling in mice after transverse aortic constriction (TAC).
Methodology/Principal Findings: In patients with severe aortic stenosis (AS) undergoing valve replacement, we detected
greater myocardial PDE5 expression than in control hearts. We observed robust expression in scattered cardiac myocytes of
those AS patients with higher LV filling pressures and BNP serum levels. Following TAC, we detected similar, focal PDE5
expression in cardiac myocytes of C57BL/6NTac mice exhibiting the most pronounced LV remodeling. To examine the effect
of cell-specific PDE5 expression, we subjected transgenic mice with cardiac myocyte-specific PDE5 overexpression (PDE5-
TG) to TAC. LV hypertrophy and fibrosis were similar as in WT, but PDE5-TG had increased cardiac dimensions, and
decreased dP/dtmax and dP/dtmin with prolonged tau (P,0.05 for all). Greater cardiac dysfunction in PDE5-TG was associated
with reduced myocardial cGMP and SERCA2 levels, and higher passive force in cardiac myocytes in vitro.
Conclusions/Significance: Myocardial PDE5 expression is increased in the hearts of humans and mice with chronic pressure
overload. Increased cardiac myocyte-specific PDE5 expression is a molecular hallmark in hypertrophic hearts with contractile
failure, and represents an important therapeutic target.
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Introduction
Sustained left ventricular (LV) pressure overload, as in aortic
stenosis (AS), causes pathological hypertrophy, reactivation of a
fetal gene program, and maladaptive molecular alterations that
initiate transition to heart failure [1]. Accumulating evidence
points to a cardioprotective role of the ubiquitous intracellular
second messenger cyclic guanosine 3’, 5’-monophosphate (cGMP)
in this pathological response [2]. In the cardiovascular system,
cGMP is generated by guanylate cyclase isoforms in response to
natriuretic peptides and nitric oxide, and its biological actions are
predominantly mediated by cGMP-dependent protein kinases
(PKG) and phosphodiesterases (PDE).
Of the 11-member PDE superfamily, PDE 1, 2, 3, 5, and 9
hydrolyze cGMP in the heart to relatively inactive GMP [3]. PDE
1, 2, and 3 exert dual-substrate specificity for cGMP and cyclic
adenosine 3’, 5’-monophosphate (cAMP), while PDE5 and PDE9
are cGMP-specific. The most widely studied cGMP-esterase is
PDE5, which is prominently expressed in vascular smooth muscle
cells (VSMC), and is therapeutically targeted in the treatment of
erectile dysfunction and pulmonary hypertension [4,5]. Under
normal physiological conditions, PDE5 expression in the heart is
low, but, in human right ventricular hypertrophy and advanced
LV failure, PDE5 is increased in cardiac myocytes, suggesting that
the enzyme has a role in the adaptation to increased stress [6,7,8].
Treatment with sildenafil, a selective PDE5 inhibitor, attenuated
LV remodeling in mice subjected to TAC, and was recently shown
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The to confer benefit in patients with stable systolic heart failure and in
heart failure patients with preserved ejection fraction and
pulmonary hypertension [9,10,11]. However, it is possible that
some of sildenafil’s cardiac effects are attributable to inhibition of
PDE1 [12]. In view of the wide expression of PDE1 in the
cardiovascular system, including in cardiac myocytes, possible
cross-reactivity is relevant [13]. Moreover, beneficial effects of
PDE5 inhibitors on cardiac remodeling could involve targeting of
other cardiac cell types including fibroblasts, smooth muscle cells,
and endothelial cells, or modulation of LV afterload via
vasodilatation of systemic resistance vessels.
In the present study, we investigated spatial PDE5 expression
patterns in myocardial tissue of patients with severe aortic stenosis
undergoing aortic valve replacement (AVR). We observed marked
PDE5 expression in scattered cardiac myocytes of patients with
increased LV filling pressures. We report a strikingly similar PDE5
expression in cardiac myocytes of mice with the most pronounced
cardiac remodeling in response to transverse aortic constriction
(TAC)-induced chronic pressure overload. Finally, by using a
transgenic approach, we show that cardiac myocyte-restricted
increased PDE5 expression during sustained pressure overload
contributes to contractile dysfunction and adverse LV remodeling.
Materials and Methods
Ethics Statement
The patient study was performed in accordance with the
Declaration of Helsinki, and approved by the Medical Ethics
Committee of University Hospital Gasthuisberg (Leuven, Belgium)
or the Ethics Committee of OLV Hospital (Aalst, Belgium). All
patients provided written informed consent.
Animal research was conducted according to the 2010/63/EU
Directive, and approved by the Ethical Committee for Laboratory
Experimentation of KU Leuven (Leuven, Belgium - permit
number: P078/2007).
Aortic Stenosis Patients
Cardiac tissue samples (n=20) were obtained from the LV
outflow tract of patients with isolated severe aortic stenosis and
chronic pressure overload during AVR surgery at University
Hospital Gasthuisberg (Leuven, Belgium) or OLV Hospital (Aalst,
Belgium). PDE5 expression was analyzed using immunohisto-
chemistry (see File S1 for details).
Experimental Animals and TAC Procedure
Mice with cardiac myocyte-specific overexpression of PDE5
(PDE5-TG) were backcrossed for 6 generations onto a C57BL/
6NTac (Taconic Inc) background [8]. Wild-type littermates served
as controls. As reported previously, PDE5 protein expression was
9-fold higher and sildenafil-inhibitable cGMP hydrolysis 10-fold
greater in PDE5-TG than in WT LV tissue (P,0.05 for both) [8].
Myocardial cyclic nucleotide concentrations and expression of
endogenous PDE isoforms at baseline did not differ between
PDE5-TG and WT [8].
Acute and chronic pressure overload was induced by TAC
(using a 27 gauge needle) in PDE5-TG and WT male age- and
body weight-matched mice. Anesthesia was induced with sodium
pentobarbital (Ceva Sante ´ Animale, 40–70 mg/kg IP), of which
the depth was controlled by monitoring muscle tone (toe pinch)
during the entire procedure. An analgesic (buprenorphine,
Schering-Plough, 0.1 mg/kg SC) was administered during the
first two days after surgery (for details see File S1).
Cardiac Imaging and Hemodynamic Measurements
Ten weeks after TAC, transthoracic echocardiography (TTE)
was used to measure end-diastolic and end-systolic dimensions and
volumes (volume=p*LVID
3/6, with LVID indicating LV internal
diameter at the level of the papillary muscles), fractional
shortening, and ejection fraction. Invasive pressure measurements
were used to determine heart rate, transaortic pressure gradient,
maximum rate of LV pressure development and decline (dP/dtmax
and dP/dtmin), and the time constant of isovolumic relaxation
(Tau, Weiss). Additionally, LV pressure-volume loops were
recorded using conductance catheter technology. Following
hemodynamic measurements, mice were euthanized and cardiac
tissue was collected for further processing. For details on cardiac
imaging and hemodynamic measurements, see File S1.
Histological and Immunoblot Analysis
Ten weeks after TAC, hearts (without auricles) were weighed,
and tibia length was measured to determine heart weight to body
weight ratios (HW/BW) and heart weight to tibia length ratios
(HW/TL). Myocardial PDE5 expression was examined using
immunohistochemical stainings of 6 mm-thick LV sections. Fur-
thermore, cardiac myocyte width was measured in laminin-stained
sections, and to assess fibrosis in the LV, the area of collagen
deposition and degree of collagen cross-links were traced on Sirius
red-stained sections using polarized light. Apoptotic cardiac
myocytes were detected by labeling DNA strand breaks using
TUNEL (ApopTag, MilliPore), according to the manufacturer’s
instructions. In addition, immunoblot techniques were used to
determine protein levels of PDE5, SERCA2, and markers of
hypertrophy and oxidative stress. For detailed methods on
immunohistochemistry and immunoblot analysis, see File S1.
Quantitative Real-time Polymerase Chain Reaction and
Cyclic Nucleotide Measurements
In mice with chronic pressure overload, myocardial expression
of genes involved in cGMP metabolism, Ca
2+-handling, cardiac
hypertrophy, apoptosis, and fibrosis was measured using RT-
qPCR (TaqMan or SYBR green PCR master mix, Life
Technologies). For a list of specific primers see Table S1. Relative
mRNA levels were analyzed using the Livak method [14].
To measure myocardial cyclic nucleotide concentrations, cyclic
nucleotides were extracted from pulverized tissue in 6% trichloro-
acetic acid, incubated at 4uC during 30 min, and centrifuged.
Supernatant was extracted 3 times with water-saturated ether and
vacuum-dried overnight. Lyophilized extracts were solubilized in
assay buffer and cGMP and cAMP concentrations were measured
using an enzyme immunoassay (GE Healthcare).
Force Measurements in Isolated Permeabilized Cardiac
Myocyte Preparations
Cardiac myocytes were isolated from pressure overloaded
PDE5-TG and WT hearts, and permeabilized. In these cells,
Ca
2+-dependent active isometric force and its Ca
2+-sensitivity, and
Ca
2+-independent passive force were determined as described
previously [15,16]. To determine cGMP/PKG-dependent mod-
ulation of the mechanical function of myofilaments, Ca
2+-force
relationships of cardiac myocytes were determined before and
after incubation in relaxing solution supplemented with the
catalytic subunit of bovine PKG, cGMP, and dithiothreitol. For
details on force measurements, see File S1.
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All data are expressed as mean6SEM. Differences between
groups were determined with an unpaired t-test (with Welch’s
Correction) or a factorial ANOVA and a Bonferroni post hoc test.
A probability value of P,0.05 was considered statistically
significant.
Results
Increased PDE5 Expression in LV Tissue from Patients
with Severe Aortic Stenosis
Patients undergoing AVR (n=20) had an aortic valve area
#0.7 cm
2, a transvalvular gradient of 5763 mmHg, increased LV
mass index of 8664 g/m
2, and no signs of obstructive coronary
artery disease. To investigate spatial distribution of PDE5 in the
heart, we performed immunohistochemical analyses of cardiac
sections from control non-pressure overloaded hearts, obtained at
autopsy (n=5), and from AS patients. In cardiac tissue of control
subjects, PDE5 expression was scarcely detectable (Figure 1A, left
panel), and predominantly present in vascular smooth muscle cells.
In contrast, in AS patients, PDE5 expression was markedly
induced in scattered cardiac myocytes (Figure 1A and 1B).
Histological examination of PDE5 immunoreactivity in cardiac
tissue of AS patients was performed on a minimum of 10 high-
power fields from 3 sections per patient and allowed a semi-
quantitative scoring of PDE5 expression on a four-point scale from
0 to 3. Grade 0 indicated no PDE5 immunoreactivity in cardiac
myocytes; grade 1, up to 1% PDE5 immunoreactive cardiac
myocytes; grade 2, between 1 and 10% of PDE5 immunoreactive
cardiac myocytes; and grade 3, PDE5 immunoreactivity of .10%
of the cardiac myocytes. Subsequently, AS patients were separated
into patients with grade 1 PDE5 expression, and those with
markedly increased PDE5 immunoreactivity (grade 2–3). AS
patients with grade 2–3 immunoreactivity (n=13) had higher
pulmonary capillary wedge pressures and serum NT-proBNP
levels than AS patients with grade 1 PDE5 immunoreactivity
(n=7) (1862v s1 1 61 mmHg, and 10906254 vs 4036221 ng/l,
respectively, P,0.05 for both).
Cardiac PDE5 Expression is Increased in Mice in Response
to Chronic Pressure Overload
To investigate PDE5 expression in a mouse model of chronic
pressure overload, we performed immunoblot and immunohisto-
chemical analyses in WT mice at baseline and after 10 weeks
TAC. Immunoblot analysis showed increased PDE5 protein
expression after chronic pressure overload (Figure 2A). Histolog-
ical examination of PDE5 immunoreactivity showed distinctly
increased PDE5 expression in scattered cardiac myocytes
(Figure 2B). A semi-quantitative scoring of PDE5 expression was
performed on a four-point scale from 0 to 3 on a minimum of 20
high-power fields from 3 sections per mouse. Grade 0 indicated no
PDE5 immunoreactivity in cardiac myocytes, grade 1; up to 1% of
cardiac myocytes with distinctly increased PDE5 immunoreactiv-
ity, grade 2; marked PDE5 immunoreactivity in up to 50% of
cardiac myocytes, and grade 3; robust immunoreactivity in .50%
of the cardiac myocytes. In a second set of mice, PDE5 expression
was quantified using PDE5 immunoblot and densitometric
analysis. In mice with a modest increase in PDE5 protein levels
(.1.5 fold versus baseline) and immunoreactivity (grade 1), we
measured intermediate LV hypertrophy, and limited LV dysfunc-
tion and dilatation (Table 1). In contrast, mice with markedly
increased PDE5 protein levels (.10-fold versus baseline) and
immunoreactivity (grade 2–3), exhibited the most severe LV
hypertrophy, LV dilatation, and impaired systolic function.
Figure 1. PDE5 expression in LV outflow tract tissue from
patients with severe aortic stenosis. (A) In cardiac tissue of control
subjects, PDE5 expression was limited. In contrast, in AS patients,
marked PDE5 immunoreactivity was present in scattered cardiac
myocytes. (B) Double immunofluorescent staining of PDE5 (green)
and desmin (red) confirmed protein expression in cardiac myocytes.
Scale bars, 25 mm.
doi:10.1371/journal.pone.0058841.g001
Figure 2. PDE5 expression in cardiac tissue from mice with
chronic pressure overload. (A) Immunoblot analysis showed
increased PDE5 protein expression after chronic pressure overload.
Protein levels of GAPDH were measured to control for sample
variability. (B) Immunohistochemical staining of PDE5 demonstrated
that increased PDE5 expression was present in cardiac myocytes.
Colocalization was confirmed in confocal images of double immuno-
fluorescent staining of PDE5 (green) and desmin (red). Scale bars,
20 mm.
doi:10.1371/journal.pone.0058841.g002
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Cardiac Dysfunction and Adverse LV Remodeling in Mice
after 10 weeks TAC
To investigate whether increased PDE5 expression in cardiac
myocytes contributes to cardiac dysfunction and adverse LV
remodeling in response to pressure overload or occurs secondary
to the maladaptive cardiac response, we compared hemodynamics
and LV remodeling in WT and PDE5-TG subjected to 10 weeks
TAC.
Pressure-volume measurements immediately (i.e. within the first
min) after TAC showed significantly and similarly increased end-
systolic pressure (ESP), and an initial abrupt decrease in stroke
volume (SV) and ejection fraction (EF), which remained similarly
depressed in both genotypes during the first 15 minutes after TAC
(Figure S1).
After 10 weeks TAC, WT sustained a higher pressure gradient
across the fixed constriction in comparison to PDE5-TG,
consistent with better preserved LV systolic function and
maximum developed pressure in WT (Table 2). These findings
were confirmed by load-independent conductance measurements,
showing better preserved preload recruitable end-systolic stroke
work in WT than in PDE5-TG (slope: 66.865.2 in 15 PDE5-TG
vs 89.666.1 in 9 WT, P,0.05). Finally, indices of diastolic
function were also impaired in PDE5-TG compared to WT
(Table 2).
In addition, TTE revealed greater LV dimensions in PDE5-TG
than in WT (LVIDS: 4.060.1 vs 3.660.2 mm and LVIDD
4.660.1 vs 4.260.1 mm, in 49 PDE5-TG vs 35 WT respectively,
both P,0.05). In PDE5-TG, the slope of the regression curves
between increasing HW/BW and end-systolic and end-diastolic
volumes was significantly different than in WT, suggesting greater
adverse remodeling with increasing hypertrophic stress (Figure 3A).
Moreover, cardiac myocyte width, measured on laminin-stained
tissue sections, increased proportionately with HW/BW in WT,
whereas PDE5-TG showed reduced cardiac myocyte width with
high HW/BW, consistent with a more dilated phenotype
(Figure 3B).
Increased Cardiac Myocyte-specific PDE5 Expression does
not Affect Myocardial Hypertrophy and Extracellular
Matrix Remodeling in Response to Sustained Pressure
Overload
Ten weeks after TAC, HW/BW and HW/TL increased
significantly and similarly in PDE5-TG and WT, compared to
baseline (Table S2). Furthermore, fetal gene expression was similar
in PDE5-TG and WT (Table S2), as well as levels of proteins
known to be markers of hypertrophy (Figure S2A). Deposition of
thick, tightly-packed red birefringent collagen fibers and thin,
loosely-assembled green birefringent collagen fibers (Figure S2B),
and fibronectin content were increased to the same extent in the
two genotypes, consistent with similar levels of mRNAs encoding
transforming growth factor (TGF)-b1 and connective tissue growth
factor (CTGF; Table S3). There was also no difference in markers
of apoptosis and oxidative stress between the two genotypes
(Figure S2B and S2C, and Table S3). Taken together, these data
Table 1. Indices of cardiac remodeling after 10 weeks TAC in WT mice with increased PDE5 expression.
Baseline 10 weeks TAC
Moderately increased PDE5
expression
Markedly increased PDE5
expression
(n=12) (n=11) (n=6)
HW/BW (mg/g) 3.524.2 6.329.0
{ 9.0217.4
{*
LVIDD (mm) 3.860.1 4.360.1
{ 5.460.2
{*
EDV (ml) 26614 3 64
{ 8568
{*
LVIDS (mm) 2.760.1 3.760.1
{ 5.160.2
{*
ESV (ml) 14612 8 64
{ 7167
{*
FS (%) 27621 5 62
{ 661
{*
EF (%) 46633 7 631 7 62
{*
HR (bpm) 485614 495621 547612
HW/BW indicates heart to body weight ratio; LVIDD, LV internal diameter during diastole; EDV, end-diastolic volume; LVIDS, LV internal diameter during systole; ESV,
end-systolic volume; FS, fractional shortening; EF, ejection fraction; and HR, heart rate.
{P,0.05 vs baseline,
*P,0.05 vs mice with moderately increased PDE5 expression.
doi:10.1371/journal.pone.0058841.t001
Table 2. Hemodynamic parameters in PDE5-TG and WT after
10 weeks TAC.
10 weeks TAC
WT (n=11) PDE5-TG (n=18)
HW/BW (mg/g) 7.260.5 6.860.2
RCA-LCA gradient
(mmHg)
78611 4765
*
Maximum pressure
(mmHg)
145671 0 6 65
*
dP/dtmax (mmHg/s) 98116809 58686375
*
dP/dtmin (mmHg/s) 296386769 259896453
*
Tau (ms) 10.961.1 13.661.0
*
HR (bpm) 580629 519622
HW/BW indicates heart to body weight ratio; RCA-LCA gradient, gradient
between right and left common carotid artery; dP/dtmax and dP/dtmin,
maximum and minimum of the first derivative of LV pressure over time; Tau,
time constant for isovolumic relaxation (Weiss); and HR, heart rate. *P,0.05 vs
WT.
doi:10.1371/journal.pone.0058841.t002
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cardiac hypertrophy, fibrosis, apoptosis, or oxidative stress in
response to sustained pressure overload.
Enhanced Cardiac Myocyte-specific PDE5 Expression
Limits the Increase in Myocardial cGMP Levels in
Response to Chronic Pressure Overload
Ten weeks after TAC, myocardial cGMP levels were lower in
PDE5-TG (0.0560.01 pmol/mg protein, n=26) than in WT
(0.1160.02 pmol/mg protein, n=15, P,0.05). This reduction
was not attributable to altered expression levels of genes encoding
soluble and particulate guanylate cyclases (sGC and pGC), and
other PDE isoforms (data not shown). In addition, myocardial
levels of cAMP, another important second messenger in the heart,
were similar in both genotypes after 10 weeks TAC (4.260.6 in
PDE5-TG vs 3.560.4 pmol/mg protein in WT, P=NS).
PDE5 Overexpression is Associated with Decreased
SERCA2 Expression and Increased Passive Force of
Cardiac Myocytes in Pressure Overloaded Hearts
To investigate the molecular mechanisms of greater contractile
dysfunction in PDE5-TG after 10 weeks TAC, we measured
cardiac levels of the sarcoplasmic reticulum (SR) Ca
2+-ATPase 2
SERCA2, and active and passive forces in isolated cardiac
myocytes.
Quantitative PCR and immunoblot analysis showed lower
SERCA2 gene and protein expression in PDE5-TG than in WT
(P,0.05, Figure 4A and 4B), consistent with more pronounced
abnormal Ca
2+-handling and contractile impairment [17].
Active forces of permeabilized cardiac myocytes from 5 PDE5-
TG (HW/BW=8.560.8 mg/g, 20 cells) and 4 WT (HW/
BW=8.562.5 mg/g, 16 cells) did not differ (13.961.7 vs
11.361.8 kN/m
2, P=NS). Ca
2+-sensitivity of isometric force
production, determined as the [Ca
2+] at which 50% of maximal
Ca
2+-activated force was reached (Figure 5A, top panel), was not
different between genotypes, and was equally decreased after
pretreatment with cGMP-dependent PKG-Ia (Figure 5A, bottom
panel). In contrast, passive forces were significantly higher in
PDE5-TG than in WT, consistent with more pronounced diastolic
dysfunction in PDE5-TG. Passive forces were again reduced after
pretreatment of cardiac myocytes with cGMP-dependent PKG-Ia
in both genotypes (Figure 5B).
Discussion
In this study we report elevated myocardial PDE5 expression in
patients with severe aortic stenosis undergoing AVR, and in mice
exposed to chronic pressure overload induced by TAC. We
detected a strikingly similar PDE5 expression pattern in cardiac
myocytes of human and murine hearts subjected to pronounced
hypertrophic stress resulting in marked LV dysfunction. To
determine whether increased PDE5 levels in cardiac myocytes
contribute to the adverse LV remodeling in response to increased
load, we took advantage of transgenic mice with cardiac myocyte-
specific PDE5 overexpression [8]. These mice display normal
hemodynamics at baseline but develop greater adverse LV
remodeling and cardiac dysfunction than WT littermates after
10 weeks TAC. Transgenic mice had a blunted myocardial cGMP
response to chronic pressure overload, lower cardiac levels of the
Figure 3. LV volumes and cardiac myocyte width in PDE5-TG and WT after 10 weeks TAC. (A) In mice with high HW/BW, TTE revealed
greater end-systolic and end-diastolic LV volumes in PDE5-TG (n=49) than in WT (n=35), resulting in a significantly steeper slope of the regression
curve, and suggesting greater propensity to LV dilatation in PDE5-TG. (B) Moreover, unlike in WT (n=13), cardiac myocyte width in PDE5-TG (n=21)
did not augment linearly with increasing HW/BW, consistent with a more dilated phenotype.
doi:10.1371/journal.pone.0058841.g003
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2+-ATPase SERCA2 and greater PKG-Ia-sensitive increas-
es in passive force of permeabilized cardiac myocytes. Taken
together, our data suggest that in the context of chronic increased
afterload, PDE5 induction in cardiac myocytes impairs contractile
function, increases myocardial passive stiffness, and is associated
with adverse LV remodeling.
In vivo animal studies have provided compelling evidence for a
protective role of cGMP signaling during various stress conditions
leading to deleterious LV remodeling [18]. Enhanced PDE5
expression has been associated with right ventricular hypertrophy
and heart failure in patients [6,7,8]. The most striking observation
in our study is a patchy PDE5 cardiac myocyte expression pattern
in those AS patients with clear signs of heart failure (i.e. higher LV
filling pressures and circulating BNP levels), and in mice with
marked adverse cardiac remodeling and dysfunction induced by
chronic pressure overload. The role of increased PDE5 in pressure
overloaded hearts has been studied using small molecule inhibitors
of cGMP hydrolysis. Multiple reports have shown a beneficial
effect of sildenafil against adverse structural and functional cardiac
remodeling in mice, and very recently also on hemodynamics in a
small-scale intervention study in severe AS patients [19]. To what
extent beneficial effects of sildenafil on cardiac remodeling involve
targeting of PDE1 [20], non-myocyte cardiac cell types, and
indirect modulation of LV afterload via vasodilatation of systemic
resistance vessels, remains incompletely understood. Our obser-
vations of prominent LV dilatation and dysfunction in mice with
transgenic overexpression of PDE5 in cardiac myocytes, suggest a
key role for cardiac myocyte PDE5 in adverse remodeling in
chronic pressure overloaded hearts.
In a recent study, 6 weeks of TAC induced concentric and
generally compensated hypertrophy in WT, but pathological
hypertrophy and amplified fibrosis with signs of heart failure in
mice with conditional cardiac myocyte-specific PDE5 overexpres-
sion [21]. Tetracycline-induced reversal of transgene expression or
sildenafil administration after 1 week TAC abrogated this
maladaptive remodeling, and ameliorated LV dilatation and
dysfunction. In our study, the degree of cardiac hypertrophy and
fibrosis was not affected in PDE5-TG after 10 weeks TAC,
possibly related to the different duration of TAC, the life-long
versus inducible overexpression of the PDE5 transgene, and the
mouse strain used [22].
The reasons for impaired LV function and remodeling in
PDE5-TG may be multiple. First, lower mRNA and protein levels
of SERCA2 are observed in transgenic mice after 10 weeks TAC.
Impaired Ca
2+-handling associated with reduced SERCA2
expression and activity is the molecular hallmark of heart failure,
and a recent target for therapeutic interventions [23]. Reduced
SERCA2 expression indirectly indicates decreased Ca
2+-transients
Figure 4. Myocardial levels of SERCA2 in PDE5-TG and WT after
10 weeks TAC. Transcript levels (A) and protein levels (B) of SERCA2,
measured using RT-qPCR and immunoblot and densitometric analysis,
respectively, were significantly lower in PDE5-TG than in WT. Transcript
and protein levels of GAPDH were measured for normalization.
*P,0.05
vs WT.
doi:10.1371/journal.pone.0058841.g004
Figure 5. Ca
2+-sensitivity of active force, and passive force in
PDE5-TG and WT cardiac myocytes after chronic pressure
overload. (A) In the Ca
2+-force relationship, the Ca
2+-sensitivity of
isometric force production represents the [Ca
2+] (plotted as a function
of pCa; pCa=2log10[Ca
2+]) evoking half-maximal force production (top
panel). Ca
2+-sensitivity did not differ between PDE5-TG and WT cardiac
myocytes, and was reduced after pretreatment with PKG (bottom panel).
(B) Passive forces were significantly greater in cardiac myocytes from
PDE5-TG compared to WT cardiac myocytes. Pretreatment of cardiac
myocytes with PKG significantly reduced the passive forces in both
genotypes. *P,0.05;
{P,0.05 vs without PKG.
doi:10.1371/journal.pone.0058841.g005
PDE5 in Chronic LV Pressure Overload
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this remains to be empirically determined via whole-cell patch
clamping.
Second, myocardial cGMP levels increased in WT but not in
PDE5-TG subjected to sustained pressure overload. These
reduced cGMP levels in pressure overloaded PDE5-TG hearts
may result in diminished PKG-dependent phosphorylation of the
cardiac-specific N2B element of titin, an extensible molecular
spring in stretched sarcomeres [24]. PKG-mediated titin phos-
phorylation causes reduction of passive forces in cardiac myocytes,
thereby representing a potential mechanism for increased passive
forces in PDE5-TG cardiac myocytes, and thus greater myocardial
stiffness and diastolic dysfunction in PDE5-TG. The observed in
vitro cGMP/PKG-dependent reduction of passive force is consis-
tent with this post-translational modulation, although changes in
titin isoform expression can also modulate passive force of cardiac
myocytes [25].
In conclusion, PDE5 expression is markedly increased in
cardiac myocytes of aortic stenosis patients with signs of heart
failure and mice with prominent adverse LV remodeling and
dysfunction in response to chronic pressure overload. Cardiac
myocyte-restricted overexpression of PDE5 impairs contractile
function and LV remodeling in pressure overloaded murine
hearts, and is associated with reduced SERCA2 levels and
increased passive cardiac myocyte forces. Increased cardiac
myocyte PDE5 expression represents a molecular hallmark during
chronic pressure overload, heralding transition to adverse LV
remodeling and dysfunction, and a future target for therapeutic
intervention.
Supporting Information
Figure S1 Hemodynamic parameters in PDE5-TG and
WT during the first fifteen minutes after aortic constric-
tion. (A) In PDE5-TG (n=9) and WT (n=7), an instantaneous
increase in end-systolic pressure is observed upon aortic banding,
followed by a progressive decrease over the following 15 minutes.
(B) Simultaneously, an abrupt and equal decrease in stroke volume
and ejection fraction is observed immediately after banding in
both genotypes.
(TIF)
Figure S2 Structural LV remodeling in pressure over-
loaded PDE5-TG and WT hearts. (A) Protein levels of several
components of the cardiac hypertrophy pathway were similar in
both genotypes after 10 weeks TAC. GAPDH protein levels were
measured to control for sample variability. (B) Cardiac fibrosis and
apoptosis were also comparable in pressure overloaded PDE5-TG
and WT. To assess the degree of fibrosis in the murine LV, the
area of collagen deposition was traced on Sirius red-stained tissue
sections using polarized light, allowing evaluation of tightly-packed
red birefringent collagen and thin, loosely-assembled green
birefringent collagen. Cardiac myocyte apoptosis was evaluated
by labeling and detecting DNA strand breaks (TUNEL). (C)
Myocardial levels of the oxidative stress markers 3-nitrotyrosine, 4-
hydroxy-2-nonenal, and malondialdehyde were similar in PDE5-
TG and WT with sustained pressure overload. GAPDH protein
levels were measured to control for sample variability. Scale
bars=50 mm.
(TIF)
Table S1 Sequences of primers and probes used for
quantitative real-time PCR. ANP and BNP indicate atrial
and brain natriuretic peptide; Bax, Bcl-2 associated X protein; Bcl-
2 and Bcl-XL, B-cell lymphoma 2 and extra large; CTGF,
connective tissue growth factor; Fas and FasL, Fas receptor and
ligand; FN, fibronectin; GAPDH, glyceraldehyde-39-phosphate-
dehydrogenase; PDE5, phosphodiesterase type 5; SERCA2,
sarcoplasmic reticulum Ca
2+-ATPase 2; and TGF-b1, transform-
ing growth factor-b1.
(DOC)
Table S2 Indices of cardiac hypertrophy in PDE5-TG
and WT after 10 weeks TAC. HW/BW indicates heart weight
to body weight ratio; HW/TL, heart weight to tibia length ratio;
and ANP and BNP, atrial and brain natriuretic peptide.
{P,0.05
vs baseline.
(DOCX)
Table S3 Indices of cardiac fibrosis and apoptosis in
PDE5-TG and WT after 10 weeks TAC. FN indicates
fibronectin; TGF-b1, transforming growth factor-b1; CTGF,
connective tissue growth factor; Bcl-2 and Bcl-XL, B-cell
lymphoma 2 and extra large; Bax, Bcl-2 associated X protein;
and Fas and FasL, Fas receptor and ligand.
(DOCX)
File S1 Supporting Materials and Methods.
(DOC)
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